Bristol Myers reported that its late-stage ALOFT-IPF trial of the oral drug admilparant met the primary endpoint at the 60 mg twice-daily dose in patients with Idiopathic Pulmonary Fibrosis.
Earnings per share came in at $0.47 compared to a Street expectation of $0.68. Net income dropped nearly 5% year-over-year (YoY) to $1.83 billion. However, revenue came in at $47.81 billion, higher than a Street estimate of $44.88 billion.